Lipitor, Atorvastatin
Lipitor, Atorvastatin Newswire (Page 9)

Lipitor, Atorvastatin Newswire (Page 9)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 9)

Results 161 - 180 of 923 in Lipitor, Atorvastatin (generic)

  1. Why Pfizer's $17 Billion Buyout of Hospira is a Super-Smart MoveRead the original story w/Photo

    Feb 6, 2015 | The Motley Fool

    Pfizer put an end to some of that speculation by announcing Thursday it would buy specialty drugmaker Hospira for $17 billion, including debt. Here's why I think Pfizer's decision to jump into the biosimilar market is both timely and likely to pay off handsomely.

    Comment?

  2. Pfizer to buy Hospira for $15 billion to bolster hospital productsRead the original story w/Photo

    Feb 5, 2015 | Reuters

    Pfizer is known for prescription medicines like impotence treatment Viagra and Lyrica for nerve pain, but many of its biggest brands, including cholesterol treatment Lipitor and painkiller Celebrex, have lost patent protection and are facing cheaper generics. The company needs new products to keep its earnings growing.

    Comment?

  3. Texas Lipitor Lawsuits Allowed to Proceed in Federal Multidistrict...Read the original story w/Photo

    Feb 5, 2015 | PRWeb

    The Firm is representing a number of clients in Lipitor lawsuits that allege the statin medication increases the risk that patients will develop Type 2 diabetes. Our Firm is representing a number of clients in Lipitor lawsuits that put forth allegations similar to those included in these complaints.

    Comment?

  4. Pfizer to buy Hospira for USD15bnRead the original story

    Feb 5, 2015 | Business World

    Pfizer said it would buy Hospira for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines. Pfizer is known for prescription medicines like impotence treatment Viagra and Lyrica for nerve pain, but many of its biggest brands, including cholesterol treatment Lipitor and painkiller Celebrex, have lost patent protection and are facing cheaper generics.

    Comment?

  5. The Reasons That Make Pfizer A Worthy Hold.Read the original story

    Feb 5, 2015 | GuruFocus.com

    The leading research-based biopharmaceutical giant Pfizer Inc. announced its fourth-quarter and full-year 2014 earnings result on January 27, 2015. While the CEO, Mr. Ian Read tried to shift the focus of investors by emphasizing on Pfizer's need to create "a sustainable high-value pipeline."

    Comment?

  6. 5 Things Pfizer, Inc.'s Management Wants You to KnowRead the original story w/Photo

    Feb 5, 2015 | The Motley Fool

    In its latest quarterly report, Pfizer delivered a 3% decline in revenue to $13.12 billion as foreign currency translation headwinds and patent exclusivity losses continued to weigh on the company. Adjusted profits fell as well, for many of the same reasons.

    Comment?

  7. Dayton-area entrepreneur on cusp of 'billion-dollar' productRead the original story w/Photo

    Feb 4, 2015 | Business Journal

    Dr. Amol Soin is setting his sights on a new drug with immense potential for pain relief. It also has huge potential for helping to create the next billion-dollar company in the Dayton region.

    Comment?

  8. Court Documents Reveal that Lawsuits Continue to Mount in Lipitor MDL ...Read the original story w/Photo

    Feb 4, 2015 | PRWeb

    Whenever we see these types of associations, we become concerned for the health of patients seeking treatment for one problem who may be putting themselves at risk for another problem. Parker Waichman LLP , a national law firm that has long been dedicated to protecting the rights of consumers who have suffered injuries due to dangerous drugs, comments on the addition of more than 100 new lawsuits filed last month in the federal litigation in the U.S. District Court, District of South Carolina.

    Comment?

  9. Federal Lipitor Lawsuits Progress, As Court Selects Cases for First...Read the original story

    Feb 3, 2015 | Personal Injury Law News

    The Firm is representing individuals in Lipitor lawsuits that allege use of the cholesterol-lowering statin medication caused patients to develop new-onset Type 2 diabetes.

    Comment?

  10. Federal Lipitor Lawsuits Progress, As Court Selects Cases for First...Read the original story w/Photo

    Feb 3, 2015 | PRWeb

    The Firm is representing individuals in Lipitor lawsuits that allege use of the cholesterol-lowering statin medication caused patients to develop new-onset Type 2 diabetes. We are pleased to see the federal Lipitor lawsuits progressing, and look forward to the litigation's first bellwether trials.

    Comment?

  11. Dr. Zorba Paster: Reading subtitles can be a workout - Tue, 03 Feb 2015 PSTRead the original story w/Photo

    Feb 3, 2015 | The Spokesman-Review

    Dear Dr. Z: I read your column about keeping the brain fit by doing crossword puzzles, Sudoku, and other "active" brain exercise such as reading. You stated that watching television was passive, and therefore does not stimulate the mind.

    Comment?

  12. Lipitor inventor takes aim at cholesterol againRead the original story w/Photo

    Feb 1, 2015 | USA Today

    Lipitor inventor takes aim at cholesterol again Roger Newton relaunched Esperion Therapeutics and went public in 2013. Check out this story on USATODAY.com: http://usat.ly/1CQSawv Esperion Therapeutics founder and chief scientific officer Roger Newton and CEO and President Tim Mayleben celebrate the company's initial public offering on the Nasdaq stock exchange in new York in June 2013.

    Comment?

  13. Lipitor Lawsuits Move Forward, as Judge Prepares to Select Cases for...Read the original story w/Photo

    Jan 30, 2015 | PRWeb

    The Firm is representing Lipitor lawsuit plaintiffs who allegedly developed Type 2diabetes due to their use of the statin medication. We look forward to the start of bellwether trials, as the outcome of these cases could provide valuable insight into jury decisions in similar Lipitor diabetes claims.

    Comment?

  14. After heart attacks, most don't get enough statinsRead the original story w/Photo

    Jan 30, 2015 | Fox News

    In the U.S., less than a third of older heart "event" patients being discharged from the hospital get the recommended high-intensity statins, according to a new study that looked at prescriptions filled. National guidelines from the American College of Cardiology and American Heart Association say the majority of patients should be on a high-dose statin following a serious heart disease-related event like heart attack or bypass surgery.

    Comment?

  15. 70 Percent of Heart Patients Don't Take Recommended StatinsRead the original story w/Photo

    Jan 29, 2015 | News Max

    In the U.S., less than a third of older heart "event" patients being discharged from the hospital get the recommended high-intensity statins, according to a new study that looked at prescriptions filled. National guidelines from the American College of Cardiology and American Heart Association say the majority of patients should be on a high-dose statin following a serious heart disease-related event like heart attack or bypass surgery.

    Comment?

  16. Cutting down on prescription drug costsRead the original story w/Photo

    Jan 29, 2015 | WPTV Local News

    You may have had sticker shock the last time you picked up a prescription - that happens with changes in drug prices or your insurance coverage. Prices can also vary drastically by store.

    Comment?

  17. Cholesterol-lowering statin drugs raise risk of cataracts, new study suggestsRead the original story w/Photo

    Jan 28, 2015 | National Post

    The millions of Canadians taking cholesterol-lowering statin drugs are at heightened risk of contracting cataracts, concludes a new study that adds fuel to heated debate over one of the world's most widely used medications. People on statins are as much as 30% more likely to develop the eye disease than those not taking the pills, suggested the University of British Columbia analysis of hundreds of thousands of patients in U.S. and Canadian health databases.

    Comment?

  18. Statins may benefit women as much as menRead the original story

    Jan 28, 2015 | WNFL-AM Green Bay

    A large international analysis finds that statin drugs reduce heart risk factors like high cholesterol as effectively in women as they do in men. The results, based on pooled data from 22 clinical trials, include a finding that reductions in deaths from any cause were similar for men and women taking statins.

    Comment?

  19. The One Thing Pfizer, Inc. Shareholders Should Worry About, and One They Shouldn'tRead the original story w/Photo

    Jan 28, 2015 | The Motley Fool

    The company reported its fourth-quarter earnings results before the opening bell on Tuesday, delivering a 3% decline in sales to $13.12 billion from Q4 2013 and reporting a 4% decline in adjusted profit per share to $0.54. Comparably, though, these results were favorable compared to Wall Street's very timid expectations of $12.9 billion in sales and just $0.53 in EPS for Q4.

    Comment?

  20. statin drugsRead the original story

    Feb 29, 2012 | InteliHealth

    Statins are a group of drugs prescribed to lower cholesterol, protect against damage from coronary-artery disease and prevent heart attack. Should you be taking statins? Statins are a group of drugs prescribed to lower cholesterol, protect against damage from coronary-artery disease and prevent heart attack.

    Comment?